

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: April 27, 2005

(use as many sheets as necessary)

**Complete if Known**

|                        |                     |
|------------------------|---------------------|
| Application Number     | 10/714,643          |
| Filing Date            | 11/18/2003          |
| First Named Inventor   | Peter A. Crooks     |
| Group Art Unit         | 1617                |
| Examiner Name          | Gregory W. Mitchell |
| Attorney Docket Number | 069962-0102         |

Sheet

1

of

1

**U.S. PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | U.S. Patent Document |                                   | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document<br>MM-DD-YYYY | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |
|--------------------|-----------------------|----------------------|-----------------------------------|---|---|--|
|                    |                       | Number               | Kind Code <sup>2</sup> (if known) |   |   |  |
|                    |                       |                      |                                   |   |   |  |
|                    |                       |                      |                                   |   |   |  |

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document |                     |                                      | Name of Patentee or<br>Applicant of Cited Documents | Date of Publication of<br>Cited Document<br>MM-DD-YYYY | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|--------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|--|--|----------------|
|                    |                       | Offic e <sup>3</sup>    | Number <sup>4</sup> | Kind Code <sup>5</sup><br>(if known) |   |  |  |                |
| YL                 | A1                    | WO                      | 95/22965            | A2                                   | Stuart L. Weg                                       | 08-31-1995   |  |                |
| YL                 | A2                    | WO                      | 97/07750            | A1                                   | Stuart L. Weg                                       | 03-06-1997   |  |                |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
|--------------------|-----------------------|--|----------------|
| YL                 | A3                    | AZEVEDO et al., "Transdermal ketamine as an adjuvant for postoperative analgesia after abdominal gynecological surgery using lidocaine epidural blockade," <i>Anesthesia and Analgesia</i> , Vol. 91, No. 6, pages 1479-1482, 2000                             |                |
| YL                 | A4                    | SHIMOYAMA et al., "Oral ketamine is antinociceptive in the rat formalin test: Role of the metabolite, norketamine," <i>Pain</i> , Vol. 81, No. 1-2, pages 85-93, 1999  |                |
| YL                 | A5                    | EBERT et al., "Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord," <i>European Journal of Pharmacology</i> , Vol. 333, No. 1, pages 99-104, 1997                                   |                |
| YL                 | A6                    | LEUNG et al., "Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine," <i>Journal of Medicinal Chemistry</i> , Vol. 29, No. 11, pages 2396-2399, 1986                                    |                |
|                    |                       |  |                |

Examiner Signature

Date Considered

6/21/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.